We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The makers of a long list of over-the-counter (OTC) drug classes with ingredients the U.S. Food and Drug Administration (FDA) says are “not generally recognized as safe and effective” must get approved new drug applications (NDAs) to continue marketing their products, or the agency will judge them misbranded, according to a proposed rule.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor